Project Grant HT94252510798
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- The Defense Health Agency awarded a $1,116,955 Project Grant to The Broad Institute, Inc. to identify new therapies and therapeutic targets in gastroesophageal cancer. This 3-year grant, running from August 15, 2023 to August 14, 2026, is funded through the Military Medical Research and Development program (CFDA 12.420). The Broad Institute, a non-profit biomedical and genomic research organization, will leverage its expertise in areas like genomic sequencing, data analysis, and translational...
- The Defense Health Agency awarded The Broad Institute, Inc. a $987,600 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target chromophobe renal cell carcinoma with mono- and bi-paratopic antibody drug conjugates. The award period runs from August 1, 2024 to July 31, 2027. As a non-profit research organization, The Broad Institute will leverage its expertise in genomics, proteomics, and computational biology to conduct this innovative biomedical research...
- The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
- This $539,904 federal Project Grant was awarded on June 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the President and Fellows of Harvard College's Harvard T.H. Chan School of Public Health. The grant will fund research to develop genomically informed morphological stromal signatures to predict lethal prostate cancer, with a performance period from June 15, 2025 to June 14, 2028. This research aims to transform healthcare...
- The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
- The federal Project Grant award in the amount of $178,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding research at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts to target the Merkel ST-MYCL-EP400 complex in Merkel cell carcinoma. The research aims to develop innovative approaches to the understanding, detection, and treatment of this rare and aggressive form of skin cancer...
- This $1,844,306 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of Michigan to cotarget the NSD1/2 paralogs in androgen receptor (AR)-driven castration-resistant prostate cancer. The research aims to transform healthcare for military service members, veterans, and the public by developing innovative medical solutions to address critical health challenges. The project will run...
- This federal Project Grant award, valued at $1,316,000.00 and awarded by the Defense Health Agency, is funding research to advance understanding of the WRN gene as a therapeutic target for microsatellite instability-high (MSI-H) cancers. The research is being conducted by The Trustees of Columbia University in the City of New York, through its Health Sciences Division, under the Military Medical Research and Development program (CFDA 12.420). The research aims to transform healthcare for...
- The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...